Oral anti-viral drug Molnaflu now widely available across India

Team L&M

Aurobindo Pharma Limited brand of molnupiravir – Molnaflu® is now available across all major Metros and towns in India. Molnupiravir (Molnaflu®) is for treatment of adult patients with COVID-19, with Sp02 >93% and who have high risk of progression of the disease, including hospitalisation or death.

The drug was earlier approved under Emergency Use Authorisation from CDSCO, India. This is the first oral antiviral approved by India, the UK agency and also by US Foods & Drugs Administration. Last week, Japan’s Ministry of Health, Labor and Welfare (MHLW) granted Special Approval for Emergency in Japan for Molnupiravir for infectious disease caused by SARS-CoV-2.

“We are delighted with the timely permission from DCGI for the licensed version of Molnupiravir (Molnaflu®) as it opens up access to an affordable treatment option for Covid19 patients and enable us to help battle the pandemic with effective and high-quality pharmaceutical products. We are glad to have partnered with MSD on this product and are committed to enhance access to this product for patients in need, in our partnered territories,” says K. Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo.

For the licensed version of Molnupiravir, Aurobindo enjoys backward integration with in-house API manufacturing which equips it with stronger control on the quality systems and supply chain. The product will be manufactured at the company’s manufacturing facilities in India that are approved by global regulatory agencies including USFDA and UKMHRA.